vMiX is a versatile RNAi platform with potential applications that extend well beyond the neurodegenerative indications where we have demonstrated its initial therapeutic potential. Expanding our vMiX license positions us to maximise the value of vMiX as a platform technology while we maintain focus on advancing our core neuroscience pipeline. We see clear opportunities to partner with companies best positioned to advance vMiX-enabled programs across cardiovascular disease, nephrology, oncology and other indications beyond our therapeutic focus.
Lisa Deschamps, CEO of AviadoBio
16 June 2026
King's College London and AviadoBio expand licensing agreement beyond neurological diseases
King's College London and AviadoBio have announced an expanded license agreement providing AviadoBio exclusive rights to apply the vMiX™ RNAi gene silencing platform across all human therapeutic areas.
AviadoBio is a gene therapy company that officially spun out from King’s in 2020. The venture was co-founded by Professor Christopher Shaw, Dr Youn Bok Lee and Dr Do Young Lee from the School of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience.
Building on their 2020 agreement, which granted AviadoBio rights to apply the platform to its pipeline of gene therapies in neurological diseases, this expansion opens potential applications across cardiovascular disease, nephrology, oncology and a range of other indications beyond the central nervous system.
Natalie John, Intellectual Property & Licensing Manager in King’s Innovation Catalyst, supported negotiations on the expanded license agreement.
About vMiX platform
vMiX is a gene-silencing platform that uses the body’s natural process called RNA interference (RNAi) to stop certain genes from making harmful proteins that cause disease. The therapy uses adeno-associated virus (AAV) to enable targeted gene silencing for up to 3 genes simultaneously. The platform also enables ‘silencing and replacement’ by including a transgene sequence within the construct, which can add in healthy replacement genes. Silencing activity is tightly controlled using tissue- or cell-specific promoters to only work in the parts of the body where disease exists.
Previously applied to treat central nervous system disorders, such as frontotemporal dementia, Alzheimer’s disease and tauopathies, the expanded license enables broader application of the platform through strategic collaborations and partnerships.
The vMiX platform reflects the depth of translational research emerging from King’s College London and the strength of our long-standing partnership with King’s spinout, AviadoBio. We are delighted to expand our agreement with AviadoBio and extend vMiX platform’s application beyond neurological disorders across all human therapeutic areas. This expanded license reflects both the versatility of the technology and the value of sustained collaboration between academia and industry in accelerating the development of innovative therapies for patients with significant unmet medical needs.
Professor Sebastien Ourselin, Assistant Principal (Innovation)
For further information
To learn more about AviadoBio's announcement, please see their press release.
In this story
Professor of Neurology and Neurogenetics
Assistant Principal (Innovation)